GlassScriptPhysician profile
Morgana Colombo
NPI 1760658942
$19,126.25
in general payments reported to CMS, 2019-2025
38 companies · $4,113 in 2025
The $4,113 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,910 · 2020: $955 · 2021: $2,443 · 2022: $1,917 · 2023: $3,025 · 2024: $3,764 · 2025: $4,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,772 · Consulting Fee: $1,000 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,771.53 |
| Consulting Fee | $1,000.00 |
| Education | $130.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,491.82 | 2019-2025 | Botox, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,037.03 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Journey Medical Corporation | $1,930.48 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,275.77 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Genzyme Corporation | $1,237.80 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,075.79 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $819.17 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $808.97 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $768.27 | 2019-2025 | |
| Pfizer INC. | $765.70 | 2019-2025 | |
| Lilly USA, LLC | $738.25 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $735.65 | 2022-2024 | Sotyktu |
| Amgen INC. | $565.85 | 2023-2025 | Otezla, Otezla, Enbrel |
| Arcutis Biotherapeutics, INC. | $536.19 | 2023-2025 | Zoryve |
| Ucb, INC. | $534.42 | 2019-2025 | Bimzelx, Cimzia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgana Colombo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.